Advertisement

Glucose-Responsive Microspheres as a Smart Drug Delivery System for Controlled Release of Insulin

  • Jiaojiao Yu
  • Qiongyan Wang
  • Haofan Liu
  • Xiaosong Shan
  • Ziyan Pang
  • Pengjin Song
  • Feng Niu
  • Liandong HuEmail author
Original Research Article
  • 30 Downloads

Abstract

Background and Objectives

Diabetes mellitus, a disease of glucose regulation, has become one of the most common medical problems in the world. At present, alternative therapy for diabetes has, to a large extent, been widely concerned with the improvement of treatment efficacy. The aims of this study were to characterize and evaluate the surface morphology of the novel glucose-responsive injectable microspheres containing insulin, along with their in vitro release and in vivo efficacy.

Methods

In this study, glucose-responsive microspheres as an emerging smart drug delivery system for controlled release of insulin were developed by an improved water-in-oil-in-water (W/O/W) double emulsion preparation method. Here, methoxypolyethylene glycol-hydrazone-4-methoxypolyethylene glycol benzoate (mPEG-Hz-mPEG4AB) was synthesized as a pH-responsive carrier.

Results

The microspheres had a good spherical structure with a particle size of 5 ~ 10 μm. Approximately 61% of insulin was released in 15 h under a high glucose environment but was barely released within the normal glucose range in in vitro studies. After a subcutaneous injection of insulin microspheres in rats, blood glucose levels rapidly decreased within 2 h and could be maintained for 2 days in the normal range. Histopathological evaluation indicated that the microspheres were almost non-irritating.

Conclusions

The pH-responsive mPEG-Hz-mPEG4AB could be used as an efficient insulin microsphere carrier, and the optimized microspheres had good morphology and sustained hypoglycemic effect.

Notes

Compliance with Ethical Standards

Funding

This work was supported by the fund of the Top Young Talents Program of Hebei Province, the Scientific Research Project of Hebei Provincial High School (No. ZD2016136), the Post-graduate’s Innovation Fund Project of Hebei University (No. hbu2019ss080) and Key Research and Development Plan of Hebei Province (No. 19272701D).

Conflict of Interest

The authors declare that they have no conflict of interest.

Ethical Approval

The protocol of the study was approved by the ‘Animal Welfare and Ethical Committee of Hebei University’. The European Community guidelines as accepted principles for the use of experimental animals were adhered to.

References

  1. 1.
    American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2011;34:S62–9.CrossRefPubMedCentralGoogle Scholar
  2. 2.
    Mo R, Jiang TY, Di J, Tai WY, Gu Z. Emerging micro- and nanotechnology based synthetic approaches for insulin delivery. Chem Soc Rev. 2014;43:3595–629.CrossRefPubMedGoogle Scholar
  3. 3.
    Tong ZZ, Zhou JY, Zhong JX, Tang QJ, Lei ZT, Luo HP, et al. Glucose- and H2O2-responsive polymeric vesicles integrated with microneedle patches for glucose-sensitive transcutaneous delivery of insulin in diabetic rats. ACS Appl Mater Interfaces. 2018;10:20014–24.CrossRefPubMedGoogle Scholar
  4. 4.
    Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:4–14.CrossRefPubMedGoogle Scholar
  5. 5.
    Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational global attitudes of patients and physicians in insulin therapy study. Diabetic Med. 2012;29:682–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Bratlie KM, York RL, Invernale MA, Langer R, Anderson DG. Materials for diabetes therapeutics. Adv Healthc Mater. 2012;1:267–84.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Kost J, Langer R. Responsive polymeric delivery systems. Adv Drug Deliver Rev. 2012;64:327–41.CrossRefGoogle Scholar
  8. 8.
    Gilroy CA, Luginbuhl KM, Chilkoti A. Controlled release of biologics for the treatment of type 2 diabetes. J Control Release. 2016;240:151–64.CrossRefPubMedGoogle Scholar
  9. 9.
    Veiseh O, Tang BC, Whitehead KA, Anderson DG, Langer R. Managing diabetes with nanomedicine: challenges and opportunities. Nat Rev Drug Discov. 2015;14:45–57.CrossRefPubMedGoogle Scholar
  10. 10.
    Gu Z, Dang TT, Ma ML, Tang BC, Cheng H, Jiang S, et al. Glucose-responsive microgels integrated with enzyme nanocapsules for closed-loop insulin delivery. ACS Nano. 2013;7:6758–66.CrossRefPubMedGoogle Scholar
  11. 11.
    Tai W, Mo R, Di J, Subramanian V, Gu X, Buse JB, et al. Bio-inspired synthetic nanovesicles for glucose-responsive release of insulin. Biomacromolecules. 2014;15:3495–502.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Li X, Fu M, Wu J, Zhang CY, Deng X, Dhinakar A, et al. pH-sensitive peptide hydrogel for glucose-responsive insulin delivery. Acta Biomater. 2017;51:294–303.CrossRefPubMedGoogle Scholar
  13. 13.
    Xu B, Jiang GH, Yu WJ, Liu DP, Zhang Y, Zhou JY, et al. H2O2-responsive mesoporous silica nanoparticles integrated with microneedle patches for the glucose-monitored transdermal delivery of insulin. J Mater Chem B. 2017;5:8200–8.CrossRefGoogle Scholar
  14. 14.
    Lim ZW, Ping Y, Miserez A. Glucose-responsive peptide coacervates with high encapsulation efficiency for controlled release of insulin. Bioconjug Chem. 2018;29:2176–80.CrossRefPubMedGoogle Scholar
  15. 15.
    Xu B, Cao QY, Zhang Y, Yu WJ, Zhu JY, Liu DP, et al. Microneedles integrated with ZnO quantum-dot-capped mesoporous bioactive glasses for glucose-mediated insulin delivery. ACS Biomater Sci Eng. 2018;4:2473–83.CrossRefGoogle Scholar
  16. 16.
    Jiang GH, Xu B, Zhu JY, Zhang Y, Liu TQ, Song G. Polymer microneedles integrated with glucose-responsive mesoporous bioactive glass nanoparticles for transdermal delivery of insulin. Biomed Phys Eng Express. 2019;5:045038.CrossRefGoogle Scholar
  17. 17.
    Liu Y, Du JJ, Yan M, Lau MY, Hu J, Han H, et al. Biomimetic enzyme nanocomplexes and their use as antidotes and preventive measures for alcohol intoxication. Nat Nanotechnol. 2013;8:187–92.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Zhang K, Wu XY. Modulated insulin permeation across a glucose-sensitive polymeric composite membrane. J Control Release. 2002;80:169–78.CrossRefPubMedGoogle Scholar
  19. 19.
    Gu Z, Aimetti AA, Wang Q, Dang TT, Zhang YL, Veiseh O, et al. Injectable nano-network for glucose-mediated insulin delivery. ACS Nano. 2013;7:4194–201.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Etrych T, Kovar L, Strohalm J, Chytil P, Rihova B, Ulbrich K. Biodegradable star HPMA polymer-drug conjugates: biodegradability, distribution and anti-tumor efficacy. J Control Release. 2011;154:241–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Bae KH, Kim YB, Lee Y, Hwang J, Park H, Park TG. Bioinspired synthesis and characterization of gadolinium-labeled magnetite nanoparticles for dual contrast T-1- and T-2-weighted magnetic resonance imaging. Bioconjug Chem. 2010;21:505–12.CrossRefPubMedGoogle Scholar
  22. 22.
    Yoshida T, Lai TC, Kwon GS, Sako K. pH- and ion-sensitive polymers for drug delivery. Expert Opin Drug Deliv. 2013;10:1497–513.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Lai TC, Bae Y, Yoshida T, Kataoka K, Kwon GS. pH-sensitive multi-PEGylated block copolymer as a bioresponsive pDNA delivery vector. Pharm Res. 2010;27:2260–73.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Zhu LJ, Shi YF, Tu CL, Wang RB, Pang Y, Qiu F, et al. Construction and application of a pH-sensitive nanoreactor via a double-hydrophilic mu warm hyperbranched polymer. Langmuir. 2010;26:8875–81.CrossRefPubMedGoogle Scholar
  25. 25.
    Yu JS, Deng HP, Xie FR, Chen WT, Zhu BS, Xu Q. The potential of pH-responsive PEG-hyperbranched polyacylhydrazone micelles for cancer therapy. Biomaterials. 2014;35:3132–44.CrossRefPubMedGoogle Scholar
  26. 26.
    Quader S, Cabral H, Mochida Y, Ishii T, Liu X, Toh K, et al. Selective intracellular delivery of proteasome inhibitors through pH-sensitive polymeric micelles directed to efficient antitumor therapy. J Control Release. 2014;188:67–77.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Jiaojiao Yu
    • 1
    • 2
    • 3
  • Qiongyan Wang
    • 1
  • Haofan Liu
    • 1
  • Xiaosong Shan
    • 2
  • Ziyan Pang
    • 3
  • Pengjin Song
    • 1
  • Feng Niu
    • 4
  • Liandong Hu
    • 1
    • 2
    Email author
  1. 1.School of Pharmaceutical Sciences, Key Laboratory of Pharmaceutical Quality Control of Hebei ProvinceHebei UniversityBaodingChina
  2. 2.Affiliated Hospital of Hebei UniversityBaodingChina
  3. 3.Xingtai Third HospitalXingtaiChina
  4. 4.NBP Pharmaceutical Company Limited, CSPC Pharmaceutical Group LimitedShijiazhuangChina

Personalised recommendations